Advertisement

Topics

Axovant’s dementia drug granted FDA fast track designation

05:51 EDT 20 Jun 2017 | Pharmaceutical Business Review

Axovant Sciences’ investigational drug nelotanserin has secured fast track designation from the US Food and Drug Administration (FDA) for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB).

Original Article: Axovant’s dementia drug granted FDA fast track designation

NEXT ARTICLE

More From BioPortfolio on "Axovant’s dementia drug granted FDA fast track designation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...